The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.
about
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myelomaIdentification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicingMicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow MicroenvironmentHypoxia and Hypoxia-Inducible Factors in LeukemiasNew drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells.Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myelomaTargeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity.Targeting hypoxia in the leukemia microenvironmentDown regulation of Wnt signaling mitigates hypoxia-induced chemoresistance in human osteosarcoma cells.Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.Bone resorption facilitates osteoblastic bone metastatic colonization by cooperation of insulin-like growth factor and hypoxia.Gambogic acid suppresses hypoxia-induced hypoxia-inducible factor-1α/vascular endothelial growth factor expression via inhibiting phosphatidylinositol 3-kinase/Akt/mammalian target protein of rapamycin pathway in multiple myeloma cells.eIF4E and eIF4GI have distinct and differential imprints on multiple myeloma's proteome and signaling.Metabolic signature identifies novel targets for drug resistance in multiple myeloma.Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features.Myeloma as a model for the process of metastasis: implications for therapyDown-regulating HIF-1α by lentivirus-mediated shRNA for therapy of triple negative breast cancer.Direct measurement of hypoxia in a xenograft multiple myeloma model by optical-resolution photoacoustic microscopy.Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche?Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myelomaIdentification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1Concise review: growth differentiation factor 15 in pathology: a clinical role?Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma.Molecular mechanisms of effectiveness of novel therapies in multiple myeloma.SIAH proteins: critical roles in leukemogenesis.Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models.Cytotherapies in multiple myeloma: a complementary approach to current treatments?Concise review: Defining and targeting myeloma stem cell-like cells.Targeting the bone marrow microenvironment in multiple myeloma.Hypoxia inducible factor-1 alpha and multiple myeloma.DNA methylation of tumor suppressor protein-coding and non-coding genes in multiple myeloma.Effect of hypoxia-inducible factors in normal and leukemic stem cell regulation and their potential therapeutic impact.Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo.A DNA-binding Molecule Targeting the Adaptive Hypoxic Response in Multiple Myeloma Has Potent Antitumor Activity.E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271.Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2ANuclear medicine imaging of multiple myeloma, particularly in the relapsed setting.HIF1-regulated ATRIP expression is required for hypoxia induced ATR activation.
P2860
Q24598483-28363F6D-E9B1-4578-B758-98AF85FC69A1Q24627782-DE1A5909-600E-4ADB-A14D-144FE2DEE4DFQ26765477-B78D9615-CB25-4D3B-911E-83B30EE48EB4Q26767167-EDD8B921-3680-4D07-A2CE-79B38408BA8EQ27004421-6697F0F0-53B7-4335-A788-4EA47AF39926Q27692033-1BC71089-C705-4B14-851F-E77129EF5CFAQ31118586-09A17408-169B-4554-A520-5C56A20DE963Q33607455-0A691B93-E203-4B77-9140-8B14962CF34CQ33917555-CE360946-56E2-470D-988A-E427FF59CDAEQ34401785-336B82E2-EDB1-4DEF-B8EB-4F4461F0BF91Q34408337-534D69A2-06A7-44E0-8FC0-4C99A384E6DCQ34683987-BCC79889-3F1B-4466-8AB0-C61DB899F8B0Q35051528-6644B841-9334-4795-962C-64C6A61281F8Q35051647-F067DEC6-E5B5-4815-8F28-8998DC49640BQ35552009-DBAD172E-3A72-4AB4-BB38-2B17F39B7081Q35612105-DC4B173E-3308-404F-98BA-224D217FBA88Q36057606-187C4AA9-EF42-416D-97BD-2BEA3BB25A95Q36079800-8395A18C-83AE-4175-879F-7E4AFCFC4155Q36213528-388913D0-E34B-46B8-AD58-744A58664584Q36237708-C8B533B6-8F2F-4C87-B864-BE76F8A69D7DQ36289608-7E2657FF-FB88-430D-9E8B-A34275797FB8Q36662044-72D8ED7D-D173-4BC3-9370-032846E0B0C6Q36717999-F1E8526D-F641-4249-9F03-BF331FEFAC3EQ37344271-E42DBDA6-F7AF-44E1-B86C-6FF3C6B2BA36Q37641801-5D481D5D-69B4-4D7C-9ACC-530519CFF2B5Q38035044-6BA64F18-20DD-41C8-8237-6EEEFBF6D3CFQ38049544-748FA95D-D59A-43A8-BE03-BC58049A0233Q38056889-40B4B8DF-5AE4-497F-A879-C22EA20B83B4Q38108819-ADB9A411-B5E2-406F-A289-67125A18D8A9Q38180656-6AE2CF97-F4DB-4B26-B9C8-94358CA4B428Q38289041-FDA3FE3F-0B40-4B0A-A142-19571418B134Q38567828-113420D9-F6ED-471B-8EF4-D53EA9007921Q38595057-DD7B6C22-1934-492B-8B76-475CFE2C0827Q38672565-F7EC3EDF-0754-4430-A05F-A12AA9F3AE7FQ38764048-330F121C-0B12-4D14-B785-7E453A1BE0CDQ38800369-7310E8C5-9CC6-48EA-B434-178D0A15D509Q38821948-8911FD16-9F21-45DA-A9A1-EED051BFFC48Q38881386-60B91F1D-18FA-4CB5-9E87-8EDD21319C0FQ39024142-778D6F55-509A-47B5-A04B-1B445F9F5171Q39186453-E626610A-AE51-4837-8F98-CAC1429184B7
P2860
The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.
@en
The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.
@nl
type
label
The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.
@en
The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.
@nl
prefLabel
The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.
@en
The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.
@nl
P2860
P50
P356
P1433
P1476
The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2011.122
P577
2011-06-03T00:00:00Z